Fecal Lactoferrin in Discriminating Inflammatory Bowel Disease from Irritable Bowel Syndrome: a Diagnostic Meta-analysis

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2014 Jul 9

PMID 25002150

Citations 11

Authors

Xing-Lu Zhou

Wen Xu

Xiao-Xiao Tang

Lai-Sheng Luo

Jiang-Feng Tu

Chen-Jing Zhang

Xiang Xu

Qin-dong Wu

Wen-Sheng Pan

Affiliations

Soon will be listed here.

Abstract

Background: To perform a meta-analysis evaluating the diagnostic ability of fecal lactoferrin (FL) to distinguish inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS).

Methods: The Medline, EMBASE, Web of Science, Cochrane library and CNKI databases were systematically searched for studies that used FL concentrations to distinguish between IBD and IBS. The sensitivity, specificity, and other diagnostic indexes of FL were pooled using a random-effects model.

Results: Seven studies, involving 1012 patients, were eligible for inclusion. In distinguishing IBD from IBS, FL had a pooled sensitivity of 0.78 (95% confidence interval [CI]: 0.75, 0.82), a specificity of 0.94 (95% CI: 0.91, 0.96), a positive likelihood ratio of 12.31 (95% CI: 5.93, 29.15), and a negative likelihood ratio of 0.23 (95% CI: 0.18, 0.29). The area under the summary receiver-operating characteristic curve was 0.94 (95% CI: 0.90, 0.98) and the diagnostic odds ratio was 52.65 (95% CI: 25.69, 107.91).

Conclusions: FL, as a noninvasive and simple marker, is useful in differentiating between IBD and IBS.

Citing Articles

Time to Kill and Time to Heal: The Multifaceted Role of Lactoferrin and Lactoferricin in Host Defense.

Ohradanova-Repic A, Prazenicova R, Gebetsberger L, Moskalets T, Skrabana R, Cehlar O Pharmaceutics. 2023; 15(4).

PMID: 37111542 PMC: 10146187. DOI: 10.3390/pharmaceutics15041056.

Diagnostic Utility of Non-invasive Tests for Inflammatory Bowel Disease: An Umbrella Review.

Shi J, Zhang Y, She Y, Goyal H, Wu Z, Xu H Front Med (Lausanne). 2022; 9:920732.

PMID: 35911403 PMC: 9337241. DOI: 10.3389/fmed.2022.920732.

Utility of Diagnostic Tests in Children With Functional Abdominal Pain Disorders.

Llanos-Chea A, Saps M Gastroenterol Hepatol (N Y). 2019; 15(8):414-422.

PMID: 31592242 PMC: 6771033.

Fecal marker levels as predictors of need for endoscopic balloon dilation in Crohn's disease patients with anastomotic strictures.

Lopes S, Andrade P, Rodrigues-Pinto E, Afonso J, Macedo G, Magro F World J Gastroenterol. 2017; 23(35):6482-6490.

PMID: 29085198 PMC: 5643274. DOI: 10.3748/wjg.v23.i35.6482.

Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into place.

Rani R, Ali R, Lee Y Intest Res. 2016; 14(4):297-304.

PMID: 27799880 PMC: 5083258. DOI: 10.5217/ir.2016.14.4.297.

References

Walker T, Land M, Kartashov A, Saslowsky T, Lyerly D, Boone J . Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007; 44(4):414-22. DOI: 10.1097/MPG.0b013e3180308d8e. View

Brock J . Lactoferrin--50 years on. Biochem Cell Biol. 2012; 90(3):245-51. DOI: 10.1139/o2012-018. View

Deeks J . Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001; 323(7305):157-62. PMC: 1120791. DOI: 10.1136/bmj.323.7305.157. View

Xiang J, OuYang Q, Li G . [Significance of fecal lactoferrin in evaluation of disease activity in ulcerative colitis]. Zhonghua Yi Xue Za Zhi. 2007; 87(32):2262-4. View

Kane S, Sandborn W, Rufo P, Zholudev A, Boone J, Lyerly D . Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003; 98(6):1309-14. DOI: 10.1111/j.1572-0241.2003.07458.x. View

DInca R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato M . Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2006; 22(4):429-37. DOI: 10.1007/s00384-006-0159-9. View

Roseth A, Schmidt P, Fagerhol M . Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999; 34(1):50-4. DOI: 10.1080/00365529950172835. View

Quigley E, Abdel-Hamid H, Barbara G, Bhatia S, Boeckxstaens G, De Giorgio R . A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol. 2012; 46(5):356-66. DOI: 10.1097/MCG.0b013e318247157c. View

Sipponen T, Savilahti E, Karkkainen P, Kolho K, Nuutinen H, Turunen U . Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2008; 14(10):1392-8. DOI: 10.1002/ibd.20490. View

10.

Kopylov U, Rosenfeld G, Bressler B, Seidman E . Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014; 20(4):742-56. DOI: 10.1097/01.MIB.0000442681.85545.31. View

11.

Gisbert J, McNicholl A, Gomollon F . Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15(11):1746-54. DOI: 10.1002/ibd.20920. View

12.

Sugi K, Saitoh O, Hirata I, Katsu K . Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol. 1996; 91(5):927-34. View

13.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

14.

Poullis A, Foster R, Northfield T, Mendall M . Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther. 2002; 16(4):675-81. DOI: 10.1046/j.1365-2036.2002.01196.x. View

15.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

16.

Leeflang M, Deeks J, Gatsonis C, Bossuyt P . Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008; 149(12):889-97. PMC: 2956514. DOI: 10.7326/0003-4819-149-12-200812160-00008. View

17.

Bernstein C, Fried M, Krabshuis J, Cohen H, Eliakim R, Fedail S . World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2009; 16(1):112-24. DOI: 10.1002/ibd.21048. View

18.

Silberer H, Kuppers B, Mickisch O, Baniewicz W, Drescher M, Traber L . Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005; 51(3-4):117-26. View

19.

Lundberg J, Hellstrom P, Fagerhol M, Weitzberg E, Roseth A . Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005; 2(2):96-102. DOI: 10.1038/ncpgasthep0094. View

20.

Schoepfer A, Trummler M, Seeholzer P, Criblez D, Seibold F . Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum. 2007; 50(10):1697-706. DOI: 10.1007/s10350-007-0303-9. View